Targeting HER2 alterations in non–small-cell lung cancer: a comprehensive review
J Zhao, Y Xia - JCO Precision Oncology, 2020 - ascopubs.org
PURPOSE HER2 is a critical gene that drives various solid tumors in addition to those of
breast cancer. For example, HER2 plays a role in non–small-cell lung cancer (NSCLC) …
breast cancer. For example, HER2 plays a role in non–small-cell lung cancer (NSCLC) …
The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer
GN Fanelli, CA Dal Pozzo, I Depetris, M Schirripa… - Cancer Cell …, 2020 - Springer
Colorectal cancer (CRC) is a complex and molecularly heterogeneous disease representing
one of the most frequent causes of cancer-related death worldwide. About 8–15% of CRCs …
one of the most frequent causes of cancer-related death worldwide. About 8–15% of CRCs …
Real-world experience in treatment of patients with non-small-cell lung cancer with Braf or Cmet exon 14 skipping mutations
U Janzic, W Shalata, K Szymczak… - International Journal of …, 2023 - mdpi.com
BRAF and cMET exon 14 skipping are rare mutations of NSCLC. The treatment sequence in
these cases for the first and second line is not clear. An international registry was created for …
these cases for the first and second line is not clear. An international registry was created for …
Efficacy and safety of immune checkpoint inhibitors in patients with advanced non–small cell lung cancer (NSCLC): a systematic literature review
G Wagner, HK Stollenwerk, I Klerings… - …, 2020 - Taylor & Francis
Background Therapeutic strategies with immune checkpoint inhibitors (ICIs) counteract the
immunosuppressive effects of programmed cell death protein-1 (PD-1) and ligand-1 (PD …
immunosuppressive effects of programmed cell death protein-1 (PD-1) and ligand-1 (PD …
Choosing the best first-line therapy: NSCLC with no actionable oncogenic driver
SY Kim, B Halmos - Lung cancer management, 2020 - Taylor & Francis
Combination platinum-based therapy has been the standard of care for the treatment of
advanced non-small-cell lung cancer (NSCLC). Immunotherapy has emerged and …
advanced non-small-cell lung cancer (NSCLC). Immunotherapy has emerged and …
[HTML][HTML] Comparison of in situ and extraction-based methods for the detection of ROS1 rearrangements in solid tumors
C Heydt, V Ruesseler, R Pappesch, S Wagener… - The Journal of Molecular …, 2019 - Elsevier
Clinical data confirmed that patients with ROS1 rearrangement are sensitive to specific
inhibitors. Therefore, reliable detection of ROS1 rearrangements is essential. Several …
inhibitors. Therefore, reliable detection of ROS1 rearrangements is essential. Several …
Unique genetic characteristics and clinical prognosis of female patients with lung cancer harboring RET fusion gene
Z Qiu, B Ye, K Wang, P Zhou, S Zhao, W Li, P Tian - Scientific Reports, 2020 - nature.com
Objectives: Since no report on the genetic characteristics of RET fusions in female patients
with lung cancer is available, this study revealed the genetic and prognostic characteristics …
with lung cancer is available, this study revealed the genetic and prognostic characteristics …
A randomized, open-label phase II study evaluating emibetuzumab plus erlotinib and emibetuzumab monotherapy in MET immunohistochemistry positive NSCLC …
DR Camidge, T Moran, I Demedts, H Grosch… - Clinical lung cancer, 2022 - Elsevier
Introduction The hepatocyte growth factor receptor MET represents a resistance mechanism
to epidermal growth factor receptor (EGFR) inhibition in EGFR mutant (mt) non–small cell …
to epidermal growth factor receptor (EGFR) inhibition in EGFR mutant (mt) non–small cell …
[HTML][HTML] Oncogenic fusions may be frequently present at resistance of EGFR tyrosine kinase inhibitors in patients with NSCLC: a brief report
D Enrico, L Lacroix, J Chen, E Rouleau… - JTO Clinical and …, 2020 - Elsevier
Introduction Despite initial benefit, virtually all patients suffering from EGFR-mutant NSCLC
experience acquired resistance to tyrosine kinase inhibitors (TKIs), driven by multiple …
experience acquired resistance to tyrosine kinase inhibitors (TKIs), driven by multiple …
Prevalence and clinicopathological associations of HER2 expression in non-small cell lung cancer: a retrospective study in Jordanian patients
O Abu Al Karsaneh, A Al Anber, M ALQudah… - Diagnostic …, 2023 - Springer
Background Human epidermal growth factor receptor 2 (HER2), a promising therapeutic
target, can be mutated, amplified, or overexpressed in different malignancies, including non …
target, can be mutated, amplified, or overexpressed in different malignancies, including non …